Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

EP: 1.Frontline Treatment Strategies for HR+/HER2- Breast Cancer

EP: 2.CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

EP: 3.CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

EP: 4.HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting

EP: 5.HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

EP: 6.Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

EP: 7.Frontline Combination Strategies in HR+/HER2- BC

EP: 8.Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

EP: 9.Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

EP: 10.HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

Now Viewing

EP: 11.Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

EP: 12.Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

EP: 13.Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

EP: 14.ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

EP: 15.Considerations for Use of ADCs in HER2-Low Breast Cancer

EP: 16.Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

EP: 17.Optimizing Management of HR+/HER2- BC: Future Directions in Care

Transcript:

Hope S. Rugo, MD, FASCO:Aditya, the SERDs, the EMERALD trial [NCT03778931] results; I haven’t seen them yet. What is your take on that?

Aditya Bardia, MD, MPH: We’ll have to look. We’ve just seen press releases from the other 2 trials, and the only data that’s published now is from EMERALD. EMERALD did meet its primary end point, and benefit in the ESR1-mutant population appeared to be larger than the overall population in the ESR1 nondetected population. It’ll be interesting to see in EMERALD-3, which is the trial with elacestrant, as well as the acelERA (NCT04576455) trial which is the trial with giredestrant, the proportion of patients with ESR1 mutation. As we get more information related to that, then we can put this in context. The other thing that’s striking is, single-agent endocrine therapy does have certain response rate or median progression-free survival. But one can imagine with combination therapy, it’s likely going to be better; that’s why it is interesting combining these oral SERDs with other targeted agents, be it PI3 kinase inhibitors or everolimus, or even continuing the CDK4/6 inhibitor. Even a patient has received in the first-line setting, in the second-line setting the field is moving toward continued CDK4/6 inhibition it’ll be interesting to combine these oral SERDs with CDK4/6 inhibitors.

Hope S. Rugo, MD, FASCO:Yes, or changing it from one to the other that we’ll talk about in just a moment.

Transcript edited for clarity.